Huimei Capital
VC Fund
Beijing, China
Huimei Capital is a VC fund in Beijing focused on Biotechnology and Health Care. Huimei Capital primarily seeks investment in the medical and healthcare ecosystem in a multi-dimensional and three-dimensional manner. It is committed to building a professional investment platform with international vision and local execution, helping early and growing medical and health companies to grow rapidly.
- Total investments:
- 35
- Last investment:
- Lead investor:
- 34%
Last updated:
For AI agents: llms.txt
Industries Huimei Capital invests in
Stages Huimei Capital invests in
Countries Huimei Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
2 more contacts available
Round size
- Series A
- $10M–$251M
- Series B
- $18M–$102M
- Series C
- $23M–$79M
Investment Focus
Industry
- Biotechnology 14 (40%)
- Health Care 11 (31%)
- Medical 10 (29%)
- Pharmaceutical 8 (23%)
- Manufacturing 6 (17%)
Stage
- Series A 11 (31%)
- Series B 11 (31%)
- Series C 6 (17%)
- Seed 1 (3%)
- Angel 1 (3%)
Country
- China 24 (69%)
- United States 3 (9%)
- Japan 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Luo Rushu
Managing Partner & Co-founder
|
Managing Partner & Co-founder | Total investments: 3 | Find email | |
Xu Wanning
Partner
|
Partner | Total investments: 0 | Find email | |
Song Longtao
Partner & Co-founder
|
Partner & Co-founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Sniper Medical Technology
|
Sniper develops accurate and intelligent molecular diagnostic solutions. Taking the next-generation fully automatic digital PCR as a breakthrough, the company has developed a droplet generation method with global independent intellectual property rights - Vibrant Injection technology and created a new path of chip-free droplet generationtechnology. It solves the pain points of high cost and complicated operation of microfluidic technology in practical application and is expected to bring subversive innovation in the field of refined medical testing. | $18M / Series B / Oct 31, 2024 | |
Chengdu Pukang Biotechnology Co.
|
Chengdu Pukang Biotechnology Co., Ltd specializes in the development, production, and supply of high-purity single molecular PEG series derivatives, polypeptide long-acting drug side chains, and their intermediates. The company focuses on serving the pharmaceutical industry with a range of chemical supplies that are crucial for drug development andmanufacturing processes. With a professional R&D team, Chengdu Pukang Biotechnology is dedicated to advancing pharmaceutical intermediates technology and providing solutions that meet the evolving needs of the healthcare sector. The company's commitment to research and development is evident in its continuous efforts to innovate and improve its product offerings to support the pharmaceutical industry. | Series B / Jun 06, 2024 | |
Osteal Therapeutics
|
Osteal Therapeutics is a clinical-stage specialty pharmaceutical company developing novel drug and device combination products for treating musculoskeletal infection. | $50M / Series D / Jun 05, 2024 | |
Xushui Internet
|
Xushui Internet provides image equipment monitoring, operation, and maintenance cloud services, large-scale equipment IoT management system, digital integration services for hospital-wide equipment, and remote collaborative image inspection system. | Series A / Mar 19, 2024 | |
|
Osteal Therapeutics
|
Osteal Therapeutics is a clinical-stage specialty pharmaceutical company developing novel drug and device combination products for treating musculoskeletal infection. | $23M / Series C / Sep 21, 2023 | |
Sensview
|
Sensview specializes in the development and production of solid-state imaging chips and detector modules. | Series A / Jul 18, 2023 | |
Zilixir Biotech
|
Zilixir Biotech develops a new protein design technology that offers possibilities for human exploration of the complex life sciences. SWORD™ protein design technology integrates binding pockets, new drug skeleton design, activity prediction, ADME/T prediction, etc., and has had some achievements in these areas, fully demonstrating theeffectiveness of protein design. | $14.1M / Series A / May 25, 2023 | |
Bio-Engine
|
Bio-Engine is a developer of high-density serum-free suspension culture technology for animal cells. Its main products include HEK293 cell serum-free medium, PK15 cell serum-free medium, etc., which can be applied to antibodies, recombinant proteins, human and livestock. Virus vaccine, cell therapy and other fields. | $43.1M / Series C / May 15, 2023 | |
Ruitai Biotechnology
|
Ruitai is a developer for ophthalmic regenerative medicine, specialising in the R&D and sale of repair materials and medical device products | $12.9M / Series A / Mar 09, 2023 | |
Xinrui Medical
|
Xinrui Medical is a domestic enterprise that engages in the research and development of polymer valves. It focuses on new polymer valves to build a complete solution for heart valve disease. The team members have long been engaged in the research and development of polymer synthesis and polymer-related medical devices. They are all from well-knownmedical device companies and have complete product development experience and mature industrialization thinking. | Seed / Mar 08, 2023 | |
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Huimei Capital invest in?
Huimei Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 35 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Huimei Capital's check size?
Huimei Capital typically joins rounds of $10M–$251M at Series A, $18M–$102M at Series B and $23M–$79M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Huimei Capital participates in.
How do I contact Huimei Capital?
Public channels for Huimei Capital include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Huimei Capital?
The team at Huimei Capital includes Luo Rushu (Managing Partner & Co-founder), Xu Wanning (Partner) and Song Longtao (Partner & Co-founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
